Journal of Preventive, Diagnostic and Treatment Strategies in Medicine

: 2022  |  Volume : 1  |  Issue : 2  |  Page : 67--75

A review on anticancer potential of Berberis aristata and berberine with focus on quantitative methods

Manasi Rokade, Vijaya Vichare, Tejaswini Neve, Bhagyashri Parande, Shashikant Dhole 
 Department of Pharmaceutical Quality Assurance, PES Modern College of Pharmacy for Ladies, Pune, Maharashtra, India

Correspondence Address:
Ms. Manasi Rokade
PES Modern College of Pharmacy for Ladies, Moshi, Pune - 412 105, Maharashtra


Berberis aristata (BA) is a traditional herbal ayurvedic medicine widely used from ancient time and has various therapeutic effect. In this review, we had tried to emphasize on its pharmacognistic as well phytochemical parameters. We had aiming to focus on estimation of berberin in extract using different analytical techniques such as high-performance liquid chromatography, high-performance thin-layer chromatography from various parts of BA plant. It contains different isoquinoline alkaloids, namely berberine, palmitine, berbamine which are contributing in the pharmacological action of BA. As it has various pharmacological actions such as anti-bacterial, anti-diarrheal, anti-inflammatory, anti-pyretic, and anti-hemorrhagic. Along with that, it is also a potential anticancer agent as its methanolic extract showed potent activity against different cell lines such as breast cancer, colon cancer, cervical cancer cell lines. In this review, we had emphasized on phamacognosy, phytochemistry, and analysis for berberine content of BA along with its anticancer potential. A brief spotlight had also given on anticancer prospective of berberine.

How to cite this article:
Rokade M, Vichare V, Neve T, Parande B, Dhole S. A review on anticancer potential of Berberis aristata and berberine with focus on quantitative methods.J Prev Diagn Treat Strategies Med 2022;1:67-75

How to cite this URL:
Rokade M, Vichare V, Neve T, Parande B, Dhole S. A review on anticancer potential of Berberis aristata and berberine with focus on quantitative methods. J Prev Diagn Treat Strategies Med [serial online] 2022 [cited 2023 Feb 8 ];1:67-75
Available from:

Full Text


Berberis aristata (BA) usually known as “Indian Barberry,” Daruhaldi, or tree turmeric is shrub that belongs to the family Berberidaceae with genus Berberis.[1] It is found in temperate and sub-tropical regions of Asia, Europe, and America. It is native to the Himalayas region of India and widely distributed in Sri Lanka, Bhutan, and hilly areas of Nepal. It is 1.8–3.6 m at elevation of 1000–3000 m in height.[2] It is extensively used in ayurvedic medicines from ancient times. Conventionally, it is used as anti-microbial, anti-bacterial, anti-pyretic, anti-hemorrhagic, anti-inflammatory, immunostimulant.[3] Available ayurvedic marketed formulations of BA are tablets, capsules, syrups which are useful in the treatment of malaria, bleeding, fever, jaundice, diabetes, skin and eye infection, hepatitis, diarrhea.[4]

 Literature search strategy

The main focus of this article is to provide pharmacognosy and anticancer potential of BA. Evidences obtained from experimental, preclinical, and clinical studies are evaluated and presented in subject area.

The data mentioned below are taken from different sources such as Scopus, Web of science, Google scholar, Elsevier, ScienceDirect, PubMed using different terms, keywords, and title words during the search. The terms used in these searches were as follows: berberine, BA, analytical methods of BA, anticancer potential of berberine, anticancer activity of BA, cancer cell lines against berberine. In this, only English articles were measured. The irrelevant information was omitted and the key features of appropriate search studies were considered. The conclusions are summarized in this review.

Taxonomical classification[5],[6]

[Table 1] shows Taxonomical Classification of Berberis aristata.{Table 1}

Pharmacognostic description



Flowers are yellowish, complete, stalked, cyclic, perigynous, actinomorphic with racemose of 11–16 flowers per raceme and average diameter of fully opened flower is 12.5 mm. The calyx is polysepalous with 3 small and 3 large seplas with 4 –5 mm long. Corolla is yellow, polypetalous with 6 petals. Androecium 5 –6 mm long with 6 stamen and gynoecium 4–5 mm broad with broad stigma and short style.[4],[5]


Fruits are edible, acidic, sour, and elliptical to oviodal covered with plum with bright red in color having length 7 mm and diameter 4 mm,[4],[5] shown in [Figure 1]a.[8]{Figure 1}


Leaves are present as cluster of 5–8 simple spiny, lanceolate, toothed, sessile, leathery, acuminate, with reticulate pinnate venation, 4–5 cm long, 1–2 cm in breadth. Leaves are light green on ventral surface and deep green on dorsal surface,[7] shown in [Figure 1]a.


Stems are cylindrical, cut tortuous pieces of varying length and thickness, bark about 0.4–0.8 cm thick, pale yellowish gray, soft, surface rough, brittle, yellow wood portion with more or hard radiate with xylem fibers. Small pith with branched stem, thin bark, short fractured surface[8],[9] is shown in [Figure 1]b.


Roots are thick, woody, cylindrical, knotty, strongly branched, cut into varying length up to 45 mm in diameter, scaly and longitudinally wrinkled, yellowish brown in color,[10] shown in [Figure 1]c.


Seeds are yellow to pink 2–5 in number with weight 25 mg.[12]



Cork containing rectangular to squarish yellow colored thin wall radially arranged cells, irregular shaped sieve elements, tangentially arranged thick-walled phloem fibers containing calcium oxalate crystal, scattered stone cells, secondary phloem consist of sieve elements and phloem fibers, transverse by multi seriate phloem rays, sieve elements in tangentially arranged bands with compressed cells altering with short, lignified phloem fibers with thick walls. Secondary xylem is broad with xylem vessels, tracheid, and xylem fibers with transversed multi seriate xylem rays.[9],[10] Showed in [Figure 2].{Figure 2}


The outer most cork composed of rectangular cork cells followed by cork cambium. The cortical region contains rectangular parenchymatous cells filled with tannins, some regions contain yellow-colored alkaloidal content.[11] Just below cortex 3–4 celled thick secondary phloem consist of sieve tube, companion cells, and phloem fibers. The secondary xylem is wide celled with vessels, fibers, tracheids, and parenchyma. The medullary rays are thin, radiating, parenchymatous with pitted alkaloidal content.[12]


Most of the parts of BA plant contain different chemical constituents majorly alkaloids like protoberberine and bisisoquinoline.[13],[14] Berberine is considered as major alkaloid found in the plant having yield of 2.23% followed by palamatine.[15] Root bark of plant contains alkaloids such as berberine, epiberberine, palmatine,[16] tetrahydropalmitine, karachine, dihydrokarachine, dehydrocaroline, jatrorhizine, and columbamine.[17] The other extracted alkaloids are oxyberberine, berbamine, aromoline, oxycanthine, and berberine chloride.[18] Alkaloids such as pakistanine, 1-O methyl pakistanine, pseudopalmatine chloride, and pseudoberberine chloride were also isolated from bark of BA.[19],[20] Berberine content varies with altitude in roots and stem of plants and also influenced by potassium and moisture content of soil. It was seen that plant growing in lower altitude has more berberine content.[21] The flowers of plant contain polyphenolic flavonoids named quercetin, meratin, rutin,[22] other acids such as E-caffeic acid and chlorogenic acid.[23] The rhizome part of plant contains heavy metals such as lead, zinc, cadmium, chromium, and manganese.[24] The major alkaloids present in plant are shown in [Figure 3].[25]{Figure 3}

As the BA is certainly available and used in traditional medicine and also exists as pharmaceutical/ayurvedic formulations, its analysis and quantification of phytoconstituents are essential. Researchers used different analytical methods for estimation of phytoconstituents in different parts of plants. This helped to develop quality standards and analyze the pharmacokinetic properties of its phytoconstituents to achieve desirable doses for its pharmacological actions. It is necessary to focus on qualitative and quantitative analytical studies for determining phytoconstituents in real samples, as they play a significant role in designing and developing pharmaceutical/ayurvedic formulations. A detailed list of various analytical methods reported for estimation of berberine from BA is given in [Table 2].{Table 2}

From the above table, it has been observed that there are various methods reported for analysis of phytoconstituents available in BA extract. It is also reported that soxhlet apparatus was used for the extraction using methanol as solvent. For high-performance liquid chromatography (HPLC) determination, most of researchers used C-18 column and acetonitrile with water as a mobile phase. For HPTLC precoated silica gel, 60 F254 plates were used by researchers using n-propanol, formic acid, water as part mobile phase with varying proportions

Anticancer potential of berberis aristata

Berberine is one of the potent agent used for anticancer therapy which is obtained from various plants such as Berberis vulgaris (barberry), BA (tree turmeric), Mahonia aquifolium (Oregon grape), Hydrastis canadensis (goldenseal), goldthread, Oregon grape, phellodendron, Tinosporia cardiofolia (Gulvel).[42] BA has been reported to have anticancer activity against different types of cancers such as breast cancer, colon cancer, cervical cancer, kidney cancer, liver cancer, lung cancer. A detailed data of anticancer activities of BA against various cancers are presented in [Table 3].{Table 3}

Serasanambati et al. and team carried out the anticancer activity of methanolic extract of BA against Michiagan Cancer Foundation-7 (MCF-7) human breast cancer cell lines. They have found that antiprolifarative effects of methanolic extracts carried out using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay exhibited a suppressive effect on cell proliferation in dose-dependent manner. It was significantly (P ≤ 0.001) decreased by viabilities of tested groups. Soft agar colony formation assay was used for the determining the in vitro anti-neoplastic activity from which 500 μg caused significant inhibition (80%, P ≤ 0.001) of colony formation. The live/dead assay used for determining the potentiating effect shows significant (P ≤ 0.001) increase of apoptotic cells on dose-dependent manner. Cell migration was carried out using in vitro scratch assay which shows significant inhibition of cell migration up to 50% when treated with 250 μg of methanolic extract for 48 h.[43] S. Kumari studied the cell viability and antiproliferative effect of alkaloids isolated from roots of BA on breast cancer and normal epithelial breast cell lines by treating the cell lines with BA1 (9.8 μg/ml), BA2 (10 μg/ml), and BA3 (10.2 μg/ml). These compounds exhibited decrease in cell viability on MCF-7 cell line and negligible effect on MCF-10A with similar conditions compared to untreated control. Antiproliferative activity using Brdu proliferation assay of compounds was determined as 51%–55% on MCF-7 cell lines and with negligible effect on MCF-10A. The cell cycle analysis of BA extracts using cell cycle phase distribution analysis G1 phase arrest on MCF-7 cell line, indicating that these compounds possess anticancer activity against breast cancer cell lines by inhibiting cell cycle progression.[44] Basanta Lamichhane et al. and team studied the anticancer activity of BA stem extract using MTT Assay against NIH/3T3, MDA-MB-231, and U-87 MG cell lines which shows significant cytotoxicity against MDA-MB-231 and U-87 MG cell lines in comparison to NIH/3T3 cell lines. At exact concentration of 40 μg the cell viability of MDA-MB-231 and U-87 MG cell lines is half of NIH/3T3.[45] Mazumdar et al. studied the cytotoxic activity of Methanolic extract of BA and Hemidesmus indicus against MCF-7 breast cancer cell line by determining the inhibition percentage with respect to cytotoxicity was found as 89% at 1000 μg/ml with IC50 value of 50 ± 0.03 g/ml, which shows dose-dependent cytotoxicity.[46] Das et al. studied the cytotoxic activity against colon cancer cell lines using MTT assay. It showed increased in dose causes incuses increment in cell killing. The IC50 value of methanolic extract was found as 1.9648 μg/ml. It was observed that methanolic extract induces a concentration-dependent inhibition of HT29 Cells. It shows due to presence of alkaloids in extract shows potent anticancer activity.[47] Sharmila et al. carried out MTT assay against HeLa cell lines to determine the anticancer effects of bark of Berberis extract, which shows concentration-dependent increment of cytotoxicity along with cell disintegration after 48 h of treatment against cell lines at higher concentrations. The IC50 value was found to be 118.97 μg/ml.[48] K. S. R. Pai et al. evaluate the antineoplastic activity of extracts of BA in ehrlich ascites carcinoma bearing mice using cisplatin as positive control. It was found that ethanolic extract increases the weight due to tumor cell proliferation and also survival time when compared to control group. The cytotoxicity was carried out using BSL test, the cisplatin and extracts reversed the tumor-induced alteration in total WBCs, RBCs, total leukocyte count, and hemoglobin content. It also shows that the ethanolic extract is more efficient for anticancer activity due to the presence of alkaloids, flavonoids present in it.[49] K. V. Anis et al. studied the effect of alkaloid extracted from BA which found to significantly inhibit the carcinogenesis induced by 20-methylcholanthrene or N-nitrosodiethylamine in dose-dependent manner in small animals after oral administration.[50]

Analysis of isolated berberine

The presence of different alkaloids in BA is responsible for the pharmacological activity. Researchers also found that these alkaloids showed potent anticancer activity. Berberine is one of the alkaloids present in BA that exhibit anticancer potential against different cancer cell lines. Berberine sulfate and hydrochloride consider as a promising agent in treating cancer.[49],[51] [Table 4] shows the recent studies of berberine against different cancer cell lines.[75]{Table 4}

From above table, it has been observed that, berberine showed good cytotoxic activity against triple negative breast cancer cell lines, from which MDA-MB-468 is the most sensitive with IC50 = 0.48 μM. Treatment of berberine with colorectal cancer cell lines showed suppression in cell viability by increasing their apoptosis level. Berberine inhibits the DNA synthesis and proliferation of pancreatic ductal adrenocarcinoma cells and also retards the development of their cell cycle. Berberine against gastric cancer cell lines shows dose-dependent impairment of cell viability. It suppress cancer cell growth and migration in a dose-dependent manner. In case of liver cancer cell line, berberine shows selective inhibitory effect on the proliferation of hepatocellular cancer cell in dose-dependent manner. Berberine shows decrease in tumor growth in glioblastoma polymorphic cells. Induction of cellular morphological alteration and decrease in number of viable cell caused by berberine against skin cancer cell lines. Berberine shows dose-dependent suppression of cellular testosterone synthesis and also proliferation of human prostate carcinoma epithelial cell lines.


Cancer or other disorders such as cardiovascular or metabolic, which causes chronic illness to require long-term treatment. Chemical therapy used for such a long duration may cause serious side effects. BA is a safe and effective natural product that is used in various pathological conditions. Thus, it is a potential choice for long-term treatment and management of various diseases. BA due to the presence of various alkaloids not only inhibits the proliferation, invasion, and metastasis of cancer but also enhances the effects of chemoradiotherapeutic treatment. Therefore, it can be considered as a drug of choice. In this article, we had tried to explain the pharmacognosy, phytochemistry, its estimation using analytical techniques, and also the anticancer potential which are already reported by the researchers. However, very few researchers have studied its activity against different cancer cell line. It has potent activity against breast cancer, colon cancer, and cervical cancer cell lines and also in various types of other cancers. However, still, there are numerous other cancer cell lines which have not been tested against BA. Considering the literature BA can be studied for remaining cancer cell lines and may exhibit good anticancer potential against them. Berbeine available from different plant sources was also reported to have anti-cancer activity against various cancer cell lines. Therefore, it can be judged that most of the plants containing berberine in sufficient amount may exhibit good anticancer potential.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1The Ayurvedic Pharmacopoeia of India. Part I. 1st ed., Vol. II. Department of Indian Systems of Medicine and Homoeopathy: Government of India, Ministry of Health and Family Welfare; 2001. p. 33-4.
2Malhotra B, Kulkarni GT, Dhiman N, Joshi DD, Chander S, Kharkwal A, et al. Recent advances on Berberis aristata emphasizing berberine alkaloid including phytochemistry, pharmacology and drug delivery system. J Herb Med 2021;27:1-11.
3Potdar D, Hirwani RR, Dhulap S. Phyto-chemical and pharmacological applications of Berberis aristata. Fitoterapia 2012;83:817-30.
4Choudhary S, Kaurav H, Madhusudan S, Chaudhary G. Daruharidra (Berberis aristata): Review based upon its ayurvedic properties. Int J Res Appl Sci Biotechnol 2021;8:98-106.
5Sharma K, Bairwa R, Chauhan N, Shrivastava B, Saini NK. Berberis aristata: A review. Int J Res Ayurveda Pharm 2011;2:383-8.
6Chaudhari VM, Kokate KK. A comprehensive review of daruharidra. Int J Res Ayurveda Med Sci 2018;1:153-9.
7Insaf A, Sharma S, Khan MF. Pharmacognostical and pharmacological aspects of Berberis aristata. World J Pharm Res 2019;8:539-49.
8Available from: [Last accessed on 2021 Dec 25].. Indian Pharmacopoeia 2018. Vol. III. The Indian Pharmacopoeia Commission, Ghaziabad: Government of India, Ministry of Health and Family Welfare; 2018. p. 3776-9.
9Upwar NK, Patel R, Waseem N, Mahobia NK. Pharmacognostic evaluation of stem of Berberis aristata DC. Pharmacogn J 2010;2:5-9.
10Rathi B, Sahu J, Koul S, Kosha RL. Detailed pharmacognostical studies on Berberis aristata DC plant. Anc Sci Life 2013;32:234-40.
11Srivastava SK, Khatoon S, Rawat AK, Mehrotra S, Pushpangadan P. Pharmacognostic evaluation of the root of Berberis aristata DC. Nat Prod Sci 2001;7:102-6.
12Rajasekaran A, Pant J. The genus Berberis linn.: A review. Pharmacogn Rev 2008;2:5-8.
13Verma S, Singla S, Goyal S. Medicinal potential of Berberis aristata: A review. Indo Am J Pharm Sci 2018;05:5516-26.
14Chakarvarti KK, Dhar DC, Siddhiqui S. Alkaloidal constituent of the bark of Berberis aristata. J Sci Ind Res 1950;9b: 161-4.
15Ray, Roy. Folkloric uses of Berberis aristata. Sci Cult 1941;b13:1-8.
16Saied S, Batool S, Naz S. Phytochemical studies of Berberis aristata. J Basic Appl Sci 2007;3:1-4.
17Rahman A, Ansari AA. Alkaloids of Berberis aristata – Isolation of aromoline and oxyberberine. J Chem Soc Pak 2011;5:283.
18Rahman AU, Ansari AA. Alkaloids of Berberis aristata – Isolation of aromoline and oxyberberine. J Chem Soc Pak 1983;5:283.
19Bhakuni DS, Shoheb A, Popali SP. Medicinal plants: Chemical constituent of Berberis aristata. Indian J Chem 1983;20:425-9.
20Andola HC, Gaira KS, Rawal RS, Rawat MS, Bhatt ID. Habitat-dependent variations in berberine content of Berberis asiatica Roxb. ex. DC. in Kumaon, Western Himalaya. Chem Biodivers 2010;7:415-20.
21Sivakumar R, Kamachandran Nair AG. Polyphenolic constituents of the flowers of Berberis aristata. J Indian Chem Soc 1991;68:531-2.
22Katiyar D, Singh RK, Singh S, Singh D, Singh V. Isolation and characterization of n-docosane from heartwood of Berberis aristata. Int J Pharm Sci Res 2011;2:331-7.
23Meena AK, Bansal P, Kumar S, Rao MM, Garg VK. Estimation of heavy metals in commonly used medicinal plants: A market basket survey. Environ Monit Assess 2010;170:657-60.
24Available from: 1a:, 1b:, 1c:, 1d: [Last accessed on 2022 Jan 20].
25Kilambi P, Dave HN. Simultaneous determination of curcumin and berberine in their pure form and from the combined extracts of Curcuma longa and Berberis aristata. Int J Appl Sci Eng 2010;8:19-26.
26Pasrija A, Singh R, Katiyar CK. Validated HPLC-UV method for the determination of berberine in raw herb daruharidra (Berberis aristata DC), its extract, and in commercially marketed ayurvedic dosage forms. Int J Ayurveda Res 2010;1:243-6.
27Kamal YT, Singh M, Tamboli ET, Parveen R, Ahmad S. Quantitative analysis of berberine in Berberis aristata fruits and in a traditional anti-inflammatory unani formulation by use of a validated HPLC method. Acta Chromatogr 2011;1:157-68.
28Shigwan H, Saklania A, Hamrapurkar PD, Mane T, Bhatt P. HPLC method development and validation for quantification of berberine from Berberis aristata and Berberis tinctoria. Int J Appl Sci Eng 2013;11:203-11.
29Rashmi S, Rajasekaran A, Pokhriyal R, Rashmi, Singh YP. Quantitative estimation of berberine in roots of different provenances of Berberis aristata DC by HPLC and study of their antifungal properties. Pharmacogn Mag 2009;5:355-8.
30Saxena V, Lal N, Rana M, Thomas A. Pharmacognostic and phytochemical analysis of Berberis aristata stem and standardization of berberine by HPLC, HPTLC and IR spectra. Int J Sci Dev Res (IJSDR) 2021;6:378-85.
31Rout KK. Estimation of berberine in ayurvedic formulations containing Berberis aristata. J AOAC Int 2008;91:1149-53.
32Mazhar M, Agrawal SS. Standardization of Berberis aristata DC and Nigella sativa L. using HPTLC and GCMS and their antineoplasia activity in 7,12-dimethylbenz[a] anthracene-induced mouse models. Front Pharmacol 2021;12:642067.
33Patel DK, Patel K, Dhanabal SP. Standardization of Berberis aristata extract through conventional and modern HPTLC techniques. Asian Pac J Trop Dis 2012:S136-40.
34Khan MI, Md Rahman A, Khalid BM, Khushtar M, Mujahid M. Quality control standardization and evaluation of antimicrobial potential of daruhaldi (Berberis aristata DC) stem bark. J Diet Suppl 2018:1-13.
35Andola HC, Rawal RS, Rawat MS, Bhatt ID, Purohit VK. Analysis of berberine content using HPTLC fingerprint of root and bark of three Himalayan berberis species. Asian J Biotechnol 2010;24:239-45.
36Rashmi, Pant J, Rajasekaran A. HPTLC fingerprinting profile of marker compound (Berberine) in roots of Berberis aristata DC. Pharmacogn J 2011;3:41-3.
37Bajpai V, Singh A, Arya KR, Srivastav M, Kumar B. Rapid screening for the adulterants of Berberis aristata using direct analysis in real-time mass spectrometry and principal component analysis for discrimination. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2015;32:799-807.
38Basera IA, Girme A, Bhatt VP, Saste G, Pawar S, Hingorani L, et al. Development of validated UHPLC-PDA with ESI-MS-MS method for concurrent estimation of magnoflorine, berbamine, columbamine, jatrorrhizine, palmatine and berberine in Berberis aristata. Acta Chromatogr 2021:1-10.
39An R, You L, Zhang Y, Wang X, Ma Y. A rapid UPLC method for simultaneous determination of eleven components in 'Ge-Gen-Qin-Lian' decoction. Pharmacogn Mag 2014;10:464-9.
40Yun BR, Weon JB, Lee J, Eom MR, Ma CJ. Simultaneous determination of 11 bioactive compounds in jaeumganghwa-tang by high performance liquid chromatography-diode array detection. Pharmacogn Mag 2014;10:S256-63.
41Neag MA, Mocan A, Echeverría J, Pop RM, Bocsan CI, Crişan G, et al. Berberine: Botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Front Pharmacol 2018;9:557.
42Serasanambati M, Chilakapati SR, Manikonda PK, Kanala JR. Anticancer activity of methanolic extract of Berberis aristata in MCF-7 human breast cancer cell lines. Int J Life Sci Biotechnol Pharm Res 2015;4:31-5.
43Kumari S. Investigating the antioxidant and anticancer effect of alkaloids isolated from root extracts of Berberis aristata. Chem Data Collect 2022;37:1-18.
44Lamichhane B, Adhikari S, Shrestha P, Shrestha BG. Study of phytochemical, antioxidant, antimicrobial and anticancer activity of Berberis aristata. J Trop Life Sci 2014;4:01-7.
45Mazumder PM, Das S, Das Sa, Das MK. Cytotoxic activity of methanolic extracts of Berberis aristata DC and Hemidesmus indicus R.Br. in MCF7 cell line. J Curr Pharm Res 2010;01:12-5.
46Das S, Das MK, Mazumder PM, Das S, Basu SP. Cytotoxic activity of methanolic extract of Berberis aristata DC on colon cancer. Glob J Pharmacol 2009;3:137-40.
47Sharmila KJ, Monisha SM, Beevi AA, Deebarathi V. Antibacterial, antioxidant, anticancer effects and GCMS analysis of Berberis aristata. Biomedicine 2020;40:286-93.
48Pai KS, Srilatha P, Suryakant K, Setty MM, Nayak PG, Rao CM, et al. Anticancer activity of Berberis aristata in ehrlich ascites carcinoma-bearing mice: A preliminary study. Pharm Biol 2012;50:270-7.
49Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001;53:763-8.
50Rauf A, Abu-Izneid T, Khalil AA, Imran M, Shah ZA, Emran TB, et al. Berberine as a potential anticancer agent: A comprehensive review. Molecules 2021;26:7368.
51Devarajan N, Jayaraman S, Mahendra J, Venkatratnam P, Rajagopal P, Palaniappan H, et al. Berberine a potent chemosensitizer and chemoprotector to conventional cancer therapies. Phytother Res 2021;35:3059-77.
52Wang Y, Liu Y, Du X, Ma H, Yao J. Berberine reverses doxorubicin resistance by inhibiting autophagy through the PTEN/Akt/mTOR signaling pathway in breast cancer. Onco Targets Ther 2020;13:1909-19.
53Lin YS, Chiu YC, Tsai YH, Tsai YF, Wang JY, Tseng LM, et al. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines. J Cell Biochem 2019;120:13531-44.
54Zhao L, Zhang C. Berberine inhibits MDA-MB-231 cells by attenuating their inflammatory responses. Biomed Res Int 2020;2020:3617514.
55Yao M, Fan X, Yuan B, Takagi N, Liu S, Han X, et al. Berberine inhibits NLRP3 Inflammasome pathway in human triple-negative breast cancer MDA-MB-231 cell. BMC Complement Altern Med 2019;19:1-11.
56El Khalki L, Maire V, Dubois T, Zyad A. Berberine impairs the survival of triple negative breast cancer cells: Cellular and molecular analyses. Molecules 2020;25:506.
57Dai W, Mu L, Cui Y, Li Y, Chen P, Xie H, et al. Berberine promotes apoptosis of colorectal cancer via regulation of the long non-coding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2)/AU-binding factor 1 (AUF1)/B-cell CLL/lymphoma 2 (Bcl-2) axis. Med Sci Monit 2019;25:730-45.
58Lü Y, Han B, Yu H, Cui Z, Li Z, Wang J. Berberine regulates the microRNA-21-ITGB4-PDCD4 axis and inhibits colon cancer viability. Oncol Lett 2018;15:5971-6.
59Liu J, Luo X, Guo R, Jing W, Lu H. Cell metabolomics reveals berberine-inhibited pancreatic cancer cell viability and metastasis by regulating citrate metabolism. J Proteome Res 2020;19:3825-36.
60Zhang C, Yang T, Chen X, Xu J, Liang D, Yi H, et al. A preliminary study on the synthetic lethal effect of berberine and olaparib on pancreatic cancer cells and its mechanism. In: IE3S Web of Conferences Sciences. Vol. 233. Les Ulis., France: EDP Sciences; 2021. p. 02023.
61Akula SM, Candido S, Libra M, Abrams SL, Steelman LS, Lertpiriyapong K, et al. Abilities of berberine and chemically modified berberine to interact with metformin and inhibit proliferation of pancreatic cancer cells. Adv Biol Regul 2019;73:1-58.
62Hu Q, Li L, Zou X, Xu L, Yi P. Berberine attenuated proliferation, invasion and migration by targeting the AMPK/HNF4α/WNT5A pathway in gastric carcinoma. Front Pharmacol 2018;9:1-17.
63Wang J, Yang S, Cai X, Dong J, Chen Z, Wang R, et al. Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer. Oncotarget 2016;7:76076-86.
64Kou Y, Tong B, Wu W, Liao X, Zhao M. Berberine improves chemo-sensitivity to cisplatin by enhancing cell apoptosis and repressing PI3K/AKT/mTOR signaling pathway in gastric cancer. Front Pharmacol 2020;11:616251.
65You HY, Xie XM, Zhang WJ, Zhu HL, Jiang FZ. Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR. In Vitro Cell Dev Biol Anim 2016;52:857-63.
66Li HL, Wu H, Zhang BB, Shi HL, Wu XJ. MAPK pathways are involved in the inhibitory effect of berberine hydrochloride ongastric cancer MGC803 cell proliferation and IL-8 secretion in vitro and in vivo. Mol Med Rep 2016;14:1430-8.
67Wang N, Wang X, Tan HY, Li S, Tsang CM, Tsao SW, et al. Berberine suppresses cyclin D1 expression through proteasomal degradation in human hepatoma cells. Int J Mol Sci 2016;17:11-9.
68Zhang P, Wang Q, Lin Z, Yang P, Dou K, Zhang R. Berberine inhibits growth of liver cancer cells by suppressing glutamine uptake. Onco Targets Ther 2019;12:11751-63.
69Li F, Dong X, Lin P, Jiang J. Regulation of Akt/FoxO3a/Skp2 axis is critically involved in berberine-induced cell cycle arrest in hepatocellular carcinoma cells. Int J Mol Sci 2018;19:327-36.
70Chuang TY, Wu HL, Min J, Diamond M, Azziz R, Chen YH. Berberine regulates the protein expression of multiple tumorigenesis-related genes in hepatocellular carcinoma cell lines. Cancer Cell Int 2017;17:1-8.
71Jin H, Jin X, Cao B, Wang W. Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis. Oncol Rep 2017;37:729-36.
72Wang J, Qi Q, Feng Z, Zhang X, Huang B, Chen A, et al. Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway. Oncotarget 2016;7:66944-58.
73Tong L, Xie C, Wei Y, Qu Y, Liang H, Zhang Y, et al. Antitumor effects of berberine on gliomas via inactivation of caspase-1-mediated IL-1β and IL-18 release. Front Oncol 2019;9:364-79.
74Liu JF, Lai KC, Peng SF, Maraming P, Huang YP, Huang AC, et al. Berberine inhibits human melanoma AS2 cell migration and invasion via affecting the FAK, uPA, and NF-κB signaling pathways and inhibits PLX4032 resistant AS2 cell migration in vitro. Molecules 2018;23:1-15.
75Tian Y, Zhao L, Wang Y, Zhang H, Xu D, Zhao X, et al. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells. Asian J Androl 2016;18:607-12.